Janus P. Ong

11.8k total citations · 7 hit papers
72 papers, 6.3k citations indexed

About

Janus P. Ong is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Janus P. Ong has authored 72 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Epidemiology, 46 papers in Hepatology and 14 papers in Surgery. Recurrent topics in Janus P. Ong's work include Liver Disease Diagnosis and Treatment (47 papers), Liver Disease and Transplantation (25 papers) and Hepatitis C virus research (23 papers). Janus P. Ong is often cited by papers focused on Liver Disease Diagnosis and Treatment (47 papers), Liver Disease and Transplantation (25 papers) and Hepatitis C virus research (23 papers). Janus P. Ong collaborates with scholars based in United States, Philippines and Saudi Arabia. Janus P. Ong's co-authors include Zobair M. Younossi, Terry Gramlich, Kevin D. Mullen, Sherif Saadeh, M Hurley, Erick M. Remer, James N. Cooper, Michael J. Sheridan, Angela Pitts and Maria Stepanova and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Janus P. Ong

67 papers receiving 6.2k citations

Hit Papers

The utility of radiological imaging in nonalcoholic fatty... 2002 2026 2010 2018 2002 2018 2008 2020 2024 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The utility of radiological imaging in nonalcoholic fatty liver disease
    2002 1.6k citations Zobair M. Younossi, Terry Gramlich et al. profile →
  2. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
    2018 603 citations Zobair M. Younossi, Maria Stepanova et al. Clinical Gastroenterology and Hepatology profile →
  3. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
    2008 513 citations Janus P. Ong, Zobair M. Younossi et al. Journal of Hepatology profile →
  4. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
    2020 373 citations Zobair M. Younossi, Maria Stepanova et al. Clinical Gastroenterology and Hepatology profile →
  5. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
    2024 156 citations Zobair M. Younossi, James M. Paik et al. Journal of Hepatology profile →
  6. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
    2023 96 citations James M. Paik, Linda Henry et al. Hepatology Communications profile →
  7. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease
    2023 71 citations Zobair M. Younossi, Maria Stepanova et al. Hepatology Communications profile →

Peers

Janus P. Ong
Jason M. Hui Australia
Stuart McPherson United Kingdom
Flora Masutti Italy
Patrik Nasr Sweden
Phunchai Charatcharoenwitthaya Thailand
James M. Paik United States
Rubén Hernáez United States
Pegah Golabi United States
Mohammad Shadab Siddiqui United States
Yuichiro Eguchi Japan
Jason M. Hui Australia
Janus P. Ong
Citations per year, relative to Janus P. Ong Janus P. Ong (= 1×) peers Jason M. Hui

Countries citing papers authored by Janus P. Ong

Since Specialization
Citations

This map shows the geographic impact of Janus P. Ong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janus P. Ong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janus P. Ong more than expected).

Fields of papers citing papers by Janus P. Ong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janus P. Ong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janus P. Ong. The network helps show where Janus P. Ong may publish in the future.

Co-authorship network of co-authors of Janus P. Ong

This figure shows the co-authorship network connecting the top 25 collaborators of Janus P. Ong. A scholar is included among the top collaborators of Janus P. Ong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janus P. Ong. Janus P. Ong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duong, Doan Thi Thuy, et al.. (2025). Putting people at the center: methods for patient journey mapping of viral hepatitis services across two LMICs in the Asia Pacific. BMC Health Services Research. 25(1). 427–427. 1 indexed citations
2.
Younossi, Zobair M., James M. Paik, Maria Stepanova, et al.. (2024). Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. Journal of Hepatology. 80(5). 694–701. 156 indexed citations breakdown →
3.
Hashida, Ryuki, Pegah Golabi, Janus P. Ong, Takumi Kawaguchi, & Zobair M. Younossi. (2024). Alcohol and Metabolic Syndrome Interaction. Clinics in Liver Disease. 28(4). 601–620.
4.
Ong, Janus P., Khalid Alswat, Saeed Hamid, & Mohamed El‐Kassas. (2023). Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region. Clinics in Liver Disease. 27(2). 287–299. 6 indexed citations
5.
Younossi, Zobair M., Maria Stepanova, Reem Q. Al Shabeeb, et al.. (2023). The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease. Hepatology Communications. 8(1). 71 indexed citations breakdown →
6.
Alqahtani, Saleh A., et al.. (2023). The impact of hepatitis B and C positive serologies on the outcomes of non‐hepatic solid organ transplantation in the United States. Journal of Viral Hepatitis. 31(4). 181–188. 1 indexed citations
7.
Ong, Janus P., et al.. (2023). Determination of Liver Function Tests and Liver Ultrasonographic Findings in Patients with Leptospirosis in a Tertiary Hospital. Acta Medica Philippina. 58(4). 17–25. 1 indexed citations
8.
Stepanova, Maria, Khaled W. Kabbara, Denise Mohess, et al.. (2022). Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. Hepatology Communications. 6(7). 1506–1515. 41 indexed citations
9.
Paik, James M., et al.. (2021). Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. Hepatology Communications. 6(1). 90–100. 35 indexed citations
10.
Younossi, Zobair M., et al.. (2021). The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. Clinical Gastroenterology and Hepatology. 20(12). 2915–2917.e1. 13 indexed citations
11.
Younossi, Zobair M., Maria Stepanova, Janus P. Ong, et al.. (2020). Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clinical Gastroenterology and Hepatology. 19(3). 580–589.e5. 373 indexed citations breakdown →
12.
Younossi, Zobair M., Linda Henry, Janus P. Ong, et al.. (2019). Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia. Alimentary Pharmacology & Therapeutics. 49(6). 644–653. 17 indexed citations
13.
14.
Younossi, Zobair M., Fatema Nader, Chunhong Bai, et al.. (2008). A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. Journal of Viral Hepatitis. 15(5). 370–378. 30 indexed citations
15.
Baranova, Ancha, Karen Schlauch, Hazem Elariny, et al.. (2006). Gene Expression of Leptin, Resistin, and Adiponectin in the White Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Obesity Surgery. 16(9). 1118–1125. 91 indexed citations
16.
Younossi, Zobair M., Francesco Gorreta, Janus P. Ong, et al.. (2005). Hepatic gene expression in patients with obesity‐related non‐alcoholic steatohepatitis. Liver International. 25(4). 760–771. 86 indexed citations
17.
Younossi, Zobair M., Ancha Baranova, Luca Del Giacco, et al.. (2005). A Genomic and Proteomic Study of the Spectrum of Nonalcoholic Fatty Liver Disease *. Hepatology. 42(3). 665–674. 170 indexed citations
18.
Ong, Janus P. & Zobair M. Younossi. (2005). Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease. 9(4). 617–634. 31 indexed citations
19.
Ong, Janus P. & Zobair M. Younossi. (2004). Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.. Cleveland Clinic Journal of Medicine. 71(Suppl_3). S17–S17. 53 indexed citations
20.
Ong, Janus P., Zobair M. Younossi, Terry Gramlich, et al.. (2001). INTERFERON?? 2B AND RIBAVIRIN IN SEVERE RECURRENT CHOLESTATIC HEPATITIS. Transplantation. 71(10). 1486–1488. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jason M. Hui Breakdown of academic impact, for papers by Stuart McPherson Breakdown of academic impact, for papers by Flora Masutti Breakdown of academic impact, for papers by Patrik Nasr Breakdown of academic impact, for papers by Phunchai Charatcharoenwitthaya Breakdown of academic impact, for papers by James M. Paik Breakdown of academic impact, for papers by Rubén Hernáez Breakdown of academic impact, for papers by Pegah Golabi Breakdown of academic impact, for papers by Mohammad Shadab Siddiqui Breakdown of academic impact, for papers by Yuichiro Eguchi
Rankless by CCL
2026